80 related articles for article (PubMed ID: 20034112)
1. UV and X-ray structural studies of a 101-residue long Tat protein from a HIV-1 primary isolate and of its mutated, detoxified, vaccine candidate.
Foucault M; Mayol K; Receveur-Bréchot V; Bussat MC; Klinguer-Hamour C; Verrier B; Beck A; Haser R; Gouet P; Guillon C
Proteins; 2010 May; 78(6):1441-56. PubMed ID: 20034112
[TBL] [Abstract][Full Text] [Related]
2. Fab'-induced folding of antigenic N-terminal peptides from intrinsically disordered HIV-1 Tat revealed by X-ray crystallography.
Serrière J; Dugua JM; Bossus M; Verrier B; Haser R; Gouet P; Guillon C
J Mol Biol; 2011 Jan; 405(1):33-42. PubMed ID: 21035463
[TBL] [Abstract][Full Text] [Related]
3. Homonuclear 1H NMR and circular dichroism study of the HIV-1 Tat Eli variant.
Watkins JD; Campbell GR; Halimi H; Loret EP
Retrovirology; 2008 Sep; 5():83. PubMed ID: 18808674
[TBL] [Abstract][Full Text] [Related]
4. High yield expression and purification of HIV-1 Tat1-72 for structural studies.
Shojania S; Henry GD; Chen VC; Vo TN; Perreault H; O'Neil JD
J Virol Methods; 2010 Mar; 164(1-2):35-42. PubMed ID: 19941902
[TBL] [Abstract][Full Text] [Related]
5. A universal anti-HIV-1 Tat epitope vaccine that is fully synthetic and self-adjuvanting.
Goldstein G; Chicca JJ
Vaccine; 2010 Jan; 28(4):1008-14. PubMed ID: 19931501
[TBL] [Abstract][Full Text] [Related]
6. Homonuclear (1)H-NMR assignment and structural characterization of human immunodeficiency virus type 1 Tat Mal protein.
Grégoire C; Péloponèse JM; Esquieu D; Opi S; Campbell G; Solomiac M; Lebrun E; Lebreton J; Loret EP
Biopolymers; 2001; 62(6):324-35. PubMed ID: 11857271
[TBL] [Abstract][Full Text] [Related]
7. RNA conformation in the Tat-TAR complex determined by site-specific photo-cross-linking.
Wang Z; Rana TM
Biochemistry; 1996 May; 35(20):6491-9. PubMed ID: 8639596
[TBL] [Abstract][Full Text] [Related]
8. Structural studies of HIV-1 Tat protein.
Bayer P; Kraft M; Ejchart A; Westendorp M; Frank R; Rösch P
J Mol Biol; 1995 Apr; 247(4):529-35. PubMed ID: 7723010
[TBL] [Abstract][Full Text] [Related]
9. Human immunodeficiency virus-1 Tat protein: immunological facets of a transcriptional activator.
Gupta S; Mitra D
Indian J Biochem Biophys; 2007 Oct; 44(5):269-75. PubMed ID: 18341200
[TBL] [Abstract][Full Text] [Related]
10. The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS.
Gavioli R; Cellini S; Castaldello A; Voltan R; Gallerani E; Gagliardoni F; Fortini C; Cofano EB; Triulzi C; Cafaro A; Srivastava I; Barnett S; Caputo A; Ensoli B
Vaccine; 2008 Jan; 26(5):727-37. PubMed ID: 18096278
[TBL] [Abstract][Full Text] [Related]
11. Functional analysis of the N-terminal domain of Tat protein of the human immunodeficiency virus type 1.
Reddy MV; Desai M; Jeyapaul J; Prasad DD; Seshamma T; Palmeri D; Khan SA
Oncogene; 1992 Sep; 7(9):1743-8. PubMed ID: 1501886
[TBL] [Abstract][Full Text] [Related]
12. Cloning, high-yield expression in Escherichia coli, and purification of biologically active HIV-1 Tat protein.
Kirsch T; Boehm M; Schuckert O; Metzger AU; Willbold D; Frank RW; Rösch P
Protein Expr Purif; 1996 Aug; 8(1):75-84. PubMed ID: 8812837
[TBL] [Abstract][Full Text] [Related]
13. Full-length HIV-1 Tat protein necessary for a vaccine.
Opi S; Péloponèse JM; Esquieu D; Watkins J; Campbell G; De Mareuil J; Jeang KT; Yirrell DL; Kaleebu P; Loret EP
Vaccine; 2004 Aug; 22(23-24):3105-11. PubMed ID: 15297062
[TBL] [Abstract][Full Text] [Related]
14. Candidate HIV-1 Tat vaccine development: from basic science to clinical trials.
Ensoli B; Fiorelli V; Ensoli F; Cafaro A; Titti F; Buttò S; Monini P; Magnani M; Caputo A; Garaci E
AIDS; 2006 Nov; 20(18):2245-61. PubMed ID: 17117011
[No Abstract] [Full Text] [Related]
15. Tat peptide-calmodulin binding studies and bioinformatics of HIV-1 protein-calmodulin interactions.
McQueen P; Donald LJ; Vo TN; Nguyen DH; Griffiths H; Shojania S; Standing KG; O'Neil JD
Proteins; 2011 Jul; 79(7):2233-46. PubMed ID: 21560167
[TBL] [Abstract][Full Text] [Related]
16. The therapeutic phase I trial of the recombinant native HIV-1 Tat protein.
Ensoli B; Fiorelli V; Ensoli F; Lazzarin A; Visintini R; Narciso P; Di Carlo A; Monini P; Magnani M; Garaci E
AIDS; 2008 Oct; 22(16):2207-9. PubMed ID: 18832884
[TBL] [Abstract][Full Text] [Related]
17. The structure of the human immunodeficiency virus type-1 TAR RNA reveals principles of RNA recognition by Tat protein.
Aboul-ela F; Karn J; Varani G
J Mol Biol; 1995 Oct; 253(2):313-32. PubMed ID: 7563092
[TBL] [Abstract][Full Text] [Related]
18. Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans.
Buttò S; Fiorelli V; Tripiciano A; Ruiz-Alvarez MJ; Scoglio A; Ensoli F; Ciccozzi M; Collacchi B; Sabbatucci M; Cafaro A; Guzmán CA; Borsetti A; Caputo A; Vardas E; Colvin M; Lukwiya M; Rezza G; Ensoli B;
J Infect Dis; 2003 Oct; 188(8):1171-80. PubMed ID: 14551888
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection.
Fanales-Belasio E; Moretti S; Fiorelli V; Tripiciano A; Pavone Cossut MR; Scoglio A; Collacchi B; Nappi F; Macchia I; Bellino S; Francavilla V; Caputo A; Barillari G; Magnani M; Laguardia ME; Cafaro A; Titti F; Monini P; Ensoli F; Ensoli B
J Immunol; 2009 Mar; 182(5):2888-97. PubMed ID: 19234184
[TBL] [Abstract][Full Text] [Related]
20. Orientation and affinity of HIV-1 Tat fragments in Tat-TAR complex determined by fluorescence resonance energy transfer.
Cao H; Tamilarasu N; Rana TM
Bioconjug Chem; 2006; 17(2):352-8. PubMed ID: 16536465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
